Acceleron Pharma, a developer of protein therapeutics for cancer and orphan diseases, has entered into a collaboration agreement to deploy QUMAS' DocCompliance to manage all of its regulatory documents, following an extensive vendor evaluation process.
Under the agreement, Acceleron will initially use DocCompliance in its research and development group to provide users with a secure, structured, and controlled environment in the Cloud.
The controlled environment in the Cloud will be useful for the creation, approval, and management of documents from all areas of the organization that have an impact on regulatory submissions including electronic common technical documents, according to the company.
Acceleron regulatory affairs specialist Suada Celikovic said, "QUMAS provides a high level of software functionality and a commitment to customer support."
QUMAS CEO Kevin O'Leary said, "We are very pleased that Acceleron Pharma has chosen our software for their regulatory compliance requirements, and particularly that they will be using the solution in the Cloud."
